Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort

• Elise Landais,

  Affiliation International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, La Jolla, California, United States of America

  ⨯
• Xiayu Huang,

  Affiliation Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America

  ⨯
• Colin Havenar-Daughton,

  Affiliations La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, California, United States of America, Department of Medicine, University of California San Diego, San Diego, California, United States of America

  ⨯
• Ben Murrell,

  Affiliation Department of Medicine, University of California San Diego, San Diego, California, United States of America

  ⨯
• Matt A. Price,

  Affiliations IAVI Medical Affairs, New York, New York, United States of America, University of California San Francisco Department of Epidemiology and Biostatistics, San Francisco, California, United States of America

  ⨯
• Lalinda Wickramasinghe,

  Affiliation International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, La Jolla, California, United States of America

  ⨯
• Alejandra Ramos,

  Affiliation International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, La Jolla, California, United States of America

  ⨯
• Charoan B. Bian,

  Affiliation International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, La Jolla, California, United States of America

  ⨯
• Melissa Simek,

  Affiliation IAVI Medical Affairs, New York, New York, United States of America

  ⨯
• Susan Allen,

  Affiliations Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, United States of America, Rwanda-Zambia HIV Research Group, Lusaka & Ndola, Zambia

  ⨯
• Etienne Karita,

  Affiliation Rwanda-Zambia HIV Research Group, Project San Francisco, Kigali, Rwanda

  ⨯
• William Kilembe,

  Affiliation Rwanda-Zambia HIV Research Group, Lusaka & Ndola, Zambia

  ⨯
• Shabir Lakhi,

  Affiliation Rwanda-Zambia HIV Research Group, Lusaka & Ndola, Zambia

  ⨯
• Mubiana Inambao,

  Affiliation Rwanda-Zambia HIV Research Group, Lusaka & Ndola, Zambia

  ⨯
• Anatoli Kamali,

  Affiliation MRC/UVRI Uganda Research Unit on AIDS, Masaka & Entebbe, Uganda

  ⨯
• Eduard J. Sanders,

  Affiliations Centre for Geographic Medicine-Coast, Kenya Medical Research Institute, Kilifi, Kenya, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Omu Anzala,

  Affiliation Kenya AIDS Vaccine Initiative, Nairobi, Kenya

  ⨯
• Vinodh Edward,

  Affiliation The Aurum Institute, Parktown, Johannesburg, South Africa

  ⨯
• Linda-Gail Bekker,

  Affiliation Desmond Tutu HIV Center, University of Cape Town, Cape Town, South Africa

  ⨯
• Jianming Tang,

  Affiliation University of Alabama Birmingham, Department of Epidemiology and Department of Medicine, Birmingham, Alabama, United States of America

  ⨯
• Jill Gilmour,

  Affiliation IAVI Human Immunology Laboratory, Imperial College of Science Technology and Medicine, Chelsea & Westminster Hospital, London, United Kingdom

  ⨯
• Sergei L. Kosakovsky-Pond,

  Affiliation Department of Medicine, University of California San Diego, San Diego, California, United States of America

  ⨯
• Pham Phung,

  Affiliation Monogram Biosciences, Laboratory Corporation of America® Holdings, San Francisco California, United States of America

  ⨯
• Terri Wrin,

  Affiliation Monogram Biosciences, Laboratory Corporation of America® Holdings, San Francisco California, United States of America

  ⨯
• Shane Crotty,

  Affiliations La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, California, United States of America, Department of Medicine, University of California San Diego, San Diego, California, United States of America, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, United States of America

  ⨯
• Adam Godzik,

  Affiliations Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, United States of America

  ⨯
•  [ ... ],
• Pascal Poignard

  * E-mail: ppoignard@iavi.org, poignard@scripps.edu, pascal.poignard@ibs.fr

  Current address: Institut de Biologie Structurale, UMR5075 CEA-CNRS, Universite de Grenoble-Alpes, Grenoble, France

  Affiliations International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, La Jolla, California, United States of America, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• [ view all ]
• [ view less ]